Warning Letter — Thomas Brunner Hygiene GmbH
The FDA issued a Warning Letter to Thomas Brunner Hygiene GmbH following a review of operations, citing violations of current Good Manufacturing Practice (cGMP) regulations for finished pharmaceuticals.
This notice affects Thomas Brunner Hygiene GmbH, their manufacturing and quality personnel, and potentially any entities involved in the distribution of their drug products in the United States.
The issuance of a Warning Letter by CDER indicates significant deviations from manufacturing standards that could affect product quality and safety. This typically results in increased regulatory scrutiny, potential import alerts, and the requirement for comprehensive corrective and preventive actions (CAPA) to resume or continue compliant operations in the U.S. market.
Quality teams should conduct a gap analysis of current manufacturing and testing procedures against cGMP requirements and ensure all facility registrations and drug listings are current and accurate before attempting to export to the U.S. market.
FDA Warning Letter issued to: Thomas Brunner Hygiene GmbH. 07/24/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/thomas-brunner-hygiene-gmbh-729018-07242026
Open in openFDA / FDA.gov